Rifaboly OZ 500 Tablet contains Rifaximin 200 mg and Ornidazole 500 mg, a potent antimicrobial combination designed for effective management of gastrointestinal infections.
Rifaximin acts locally in the gut to inhibit bacterial growth without systemic absorption, while Ornidazole provides antiprotozoal and anaerobic bacterial coverage, ensuring comprehensive treatment of mixed infections. Together, they help in rapid symptom relief from diarrhea, dysentery, and abdominal discomfort, restoring intestinal health efficiently.
Clinically, Rifaboly OZ 500 Tablet is indicated for traveler’s diarrhea, infectious gastroenteritis, dysentery, and mixed bacterial/amoebic gut infections, making it a reliable therapy in outpatient and hospital settings. Its tablet form ensures accurate dosing, ease of administration, and patient compliance.
From a business perspective, Rifaboly OZ 500 Tablet strengthens the antimicrobial and GI therapy segment, widely prescribed in clinics, hospitals, and gastroenterology centers, offering consistent demand, repeat prescriptions, and strong prescriber trust.